BIOANALYTICAL SYSTEMS INC BASI Cash Flow

Bioanalytical systems inc (BASI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10
Operating activities:
Net loss
-2,150	-2,131	-790	-1,280	-929	-305	-194	235	531	893	884	-1,382	-2,036	-2,707	-3,230	-1,904	7	411	1,099	1,406	143	-226	-1,070	-414	-53	-145	773	-2,175	-2,997	-4,514	-6,317	-2,530	-1,866	445	2,302	0	0	0
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition:
Depreciation and amortization
3,066	2,736	2,717	2,752	2,417	2,184	1,875	1,537	1,602	1,688	1,680	1,828	1,728	1,610	1,556	1,399	1,395	1,402	1,437	1,471	1,528	1,572	1,597	1,605	1,614	1,652	1,723	1,867	2,041	2,200	2,278	2,284	2,230	2,155	2,134	0	0	0
Amortization finance lease
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee stock compensation expense
358	334	278	228	190	125	134	108	80	43	19	24	23	40	45	46	60	65	79	86	87	66	84	103	135	198	225	151	145	110	83	149	151	146	153	0	0	0
Decrease in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-189	-323	-336	-456	-487	-530	-562	-163	918	787	535	477	-601	92	-48	-246	-73	0	0	0	-	-	-	-
Provision for doubtful accounts, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on interest rate swaps
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31	0	0	0
Gain on disposal of property and equipment
-	-	-1	2	2	4	0	-3	0	-1	5	7	4	2	-14	0	-3	-4	7	0	0	0	-	-	-	-	13	-416	-429	-451	-451	-22	-3	8	9	0	0	0
Unrealized foreign currency gains
18	-5	159	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	51	52	16	16	0	0	0
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
5,226	4,616	3,087	1,543	320	492	589	1,208	-53	-101	941	-872	-336	458	-1,639	-38	464	-745	1,084	62	-154	384	-910	606	259	473	25	-1,450	-1,083	-1,719	-902	-433	-574	-206	236	0	0	0
Inventories
101	-138	-87	155	103	241	269	-100	-119	-436	-540	-412	-297	-67	-13	-85	-256	-228	-98	26	165	211	185	56	-145	-252	-277	-266	-202	-159	20	98	288	244	-37	0	0	0
Income tax accruals
70	94	-3	40	8	-15	-82	-95	-57	-61	7	11	-13	6	-17	-28	9	-9	10	35	-2	1	-10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Prepaid expenses and other assets
609	660	113	569	377	131	77	-96	-18	365	14	-160	374	200	27	229	-48	-263	97	-442	-386	209	345	686	505	228	9	-170	-271	-378	-414	-376	-195	-42	-17	0	0	0
Accounts payable
587	2,030	1,019	1,609	1,049	775	980	431	-165	-1,321	-913	-1,177	-181	1,702	1,122	1,475	722	-468	259	-923	-805	-290	-863	-416	-218	-696	-269	1,479	1,258	1,546	2,375	994	132	805	-482	0	0	0
Accrued expenses
756	1,198	849	959	-307	242	103	-126	-4	74	113	367	-17	324	-621	-243	4	-362	-132	-265	-357	-194	153	87	237	253	-378	-792	-714	-616	305	285	368	213	-86	0	0	0
Customer advances
4,364	3,338	1,156	1,116	2,066	1,646	1,610	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Customer advances
-	-	-	-	-	-	-	-	-	-	-134	-142	683	1,041	-300	398	-402	-372	424	-313	395	205	175	945	412	564	-197	-1,254	-1,003	-1,264	-559	-800	-854	-1,126	-1,010	0	0	0
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,199	1,790	1,917	2,104	1,644	1,119	487	1,684	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by operating activities
1,079	2,324	1,777	2,844	3,556	3,634	3,487	2,196	1,517	987	1,236	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-200	-1,047	-1,058	941	1,088	0	0	0
Investing activities:
Capital expenditures
0	10,194	-	-	-	1,826	1,317	1,060	622	417	347	632	782	1,195	1,256	1,638	1,868	1,511	1,467	813	571	561	490	336	146	49	8	125	285	388	1,090	1,519	1,639	1,575	1,174	0	0	0
Cash paid in acquisition
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of equipment
-	-	-	-	-	-	-	-	-	-	8	8	6	5	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,605	-1,835	-1,478	-1,434	-813	-571	-561	-490	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-13,282	-13,630	-8,149	-12,951	-9,861	-8,583	-8,074	-1,058	-618	-414	-339	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-860	-1,519	-1,639	-1,575	-1,174	0	0	0
Financing activities:
Payments on finance lease liability
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of long-term debt
1,061	935	909	1,253	671	500	331	222	3,505	3,580	3,721	3,863	720	786	786	786	786	786	786	786	5,608	5,663	5,516	5,468	596	471	588	605	650	713	735	753	744	1,240	1,756	0	0	0
Payments of debt issuance costs
183	193	94	0	0	124	-	-	169	197	214	241	113	85	68	0	0	0	-	-	-	-	194	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Payments on revolving line of credit
39,868	33,301	28,662	19,493	13,965	10,626	7,545	7,895	9,778	13,566	11,516	14,638	12,904	9,592	11,304	10,003	9,431	9,116	7,740	6,568	4,531	4,020	10,542	14,587	20,339	23,315	21,814	23,227	24,033	26,201	27,695	28,862	30,442	30,777	30,917	0	0	0
Borrowings on revolving line of credit
42,074	34,027	29,725	20,065	14,374	10,626	7,545	0	0	0	-	-	-	-	12,576	11,554	10,559	9,460	7,624	6,568	4,531	4,332	9,329	14,255	19,526	22,521	21,785	22,296	23,746	25,910	27,793	28,625	30,428	30,570	31,068	0	0	0
Borrowings on construction loan
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Borrowings on capex line of credit
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of capital lease obligations
-	-	-	0	0	138	-	127	126	124	127	156	210	244	277	282	259	271	279	287	296	285	276	268	259	296	330	433	546	604	655	610	1,333	1,328	1,341	0	0	0
Borrowings on long-term loan
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	3	3	4	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	413	54	-741	-1,213	-1,144	-513	-84	-1,513	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
11,881	11,094	6,205	9,155	6,153	4,739	4,926	-599	-646	73	-849	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,164	-1,633	2,515	1,831	1,660	0	0	0
Net decrease in cash and cash equivalents
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93	122	64	-4	-127	-84	-32	-1	40	28	-16	-18	-24	-37	-23	-33	0	0	0
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-210	-	-	253	646	48	427	-34	-116	-52	-24	-83	-344	-543	-220	157	-94	-323	423	239	171	583	-96	-713	-1,742	-2,242	-4,223	-219	1,174	1,541	0	0	0
Supplemental disclosure of cash flow information:
Cash paid for interest
835	720	566	462	364	301	233	189	185	221	230	296	332	311	312	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preclinical Research Services acquisition:
Assets acquired
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities assumed
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48	65	77	79	81	0	0	0	-	-	-	-	-	-	-	-
Cash paid
0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Smithers Avanza Toxicology Services LLC acquisition
Net loss
-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-